Radioactive pneumonia, immune pneumonia
Conditions
Interventions
Immune pneumonia group / Radiation pneumonia group:None
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The informed consent form has been signed, and based on the researcher's judgment, the patient is able to comply with the study protocol and sign a written informed consent form; 2. NSCLC patients confirmed by histopathology and clinically diagnosed with RP or CIP after radiotherapy or immune checkpoint inhibitor treatment, and who have not yet received treatment with glucocorticoids or other drugs; 3. Age>=18 years old, less than 75 years old; 4. The ECOG PS score for the Eastern Cancer Collaboration Group ranges from 0 to 3 points; 5. Individuals without contraindications for bronchoalveolar lavage;
Exclusion criteria
Exclusion criteria: 1. Poor patient compliance and violation of trial regulations; 2. Dysfunction of important liver and kidney organs occurs, such as myocardial infarction, angina pectoris, and significant elevation of liver transaminase; 3. Have suffered from any disease requiring systemic treatment with corticosteroids or other immunosuppressive drugs within the 14 days prior to enrollment; 4. Within the first 4 weeks before enrollment, there has been a serious infection, including but not limited to hospitalization for infection complications, bacteremia, or severe pneumonia; 5. Severe chronic or active infections (including tuberculosis infections, etc.) that require systemic (oral or intravenous) antibiotic treatment within 14 days prior to enrollment; 6. Untreated patients with chronic hepatitis B, HBV carriers with hepatitis B virus (HBV) DNA>=500 IU/mL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Non active carriers of hepatitis B and surface antigen (HBsAg), stable carriers of hepatitis B patients (HBV DNA<500 IU/mL) who have been treated, and cured hepatitis C patients can be included in the study; 7. Known history of HIV infection; 8.Received any other investigational drug treatment or participated in other clinical trials within 28 days;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate based on single-cell sequencing guidance measures;Molecular mechanisms of the immune microenvironment in severe pneumonia; | — |
Countries
China
Contacts
Public ContactSun Jianguo
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed